U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Stage 3 Neuroblastoma

MedGen UID:
236894
•Concept ID:
C1336257
•
Neoplastic Process
Synonym: Stage III Neuroblastoma

Definition

Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement. The midline is defined as the vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column. (cancer.gov) [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVStage 3 Neuroblastoma

Professional guidelines

PubMed

Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B
Pediatr Blood Cancer 2011 Apr;56(4):578-83. Epub 2010 Dec 9 doi: 10.1002/pbc.22693. PMID: 21298742
Management and outcome of stage 3 neuroblastoma.
Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK
Eur J Cancer 2009 Jan;45(1):90-8. Epub 2008 Nov 6 doi: 10.1016/j.ejca.2008.09.016. PMID: 18996003Free PMC Article
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.
Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A, Casale F, Mazzocco K, Cecchetto G, Rizzo A, Bernardi B; Italian Cooperative Group for Neuroblastoma
Ann Oncol 2002 Jun;13(6):956-64. doi: 10.1093/annonc/mdf165. PMID: 12123342

Recent clinical studies

Etiology

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S
Clin Cancer Res 2023 Apr 14;29(8):1546-1556. doi: 10.1158/1078-0432.CCR-22-3032. PMID: 36749880Free PMC Article
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR
Pediatr Blood Cancer 2014 Nov;61(11):1932-9. Epub 2014 Jul 7 doi: 10.1002/pbc.25134. PMID: 25044743
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B
Pediatr Blood Cancer 2011 Apr;56(4):578-83. Epub 2010 Dec 9 doi: 10.1002/pbc.22693. PMID: 21298742
Management and outcome of stage 3 neuroblastoma.
Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK
Eur J Cancer 2009 Jan;45(1):90-8. Epub 2008 Nov 6 doi: 10.1016/j.ejca.2008.09.016. PMID: 18996003Free PMC Article
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK; Children's Oncology Group
Pediatr Blood Cancer 2009 Jan;52(1):44-50. doi: 10.1002/pbc.21784. PMID: 18937318Free PMC Article

Diagnosis

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S
Clin Cancer Res 2023 Apr 14;29(8):1546-1556. doi: 10.1158/1078-0432.CCR-22-3032. PMID: 36749880Free PMC Article
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR
Pediatr Blood Cancer 2014 Nov;61(11):1932-9. Epub 2014 Jul 7 doi: 10.1002/pbc.25134. PMID: 25044743
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B
Pediatr Blood Cancer 2011 Apr;56(4):578-83. Epub 2010 Dec 9 doi: 10.1002/pbc.22693. PMID: 21298742
123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL
J Nucl Med 2009 Aug;50(8):1237-43. Epub 2009 Jul 17 doi: 10.2967/jnumed.108.060467. PMID: 19617326
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.
Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A, Casale F, Mazzocco K, Cecchetto G, Rizzo A, Bernardi B; Italian Cooperative Group for Neuroblastoma
Ann Oncol 2002 Jun;13(6):956-64. doi: 10.1093/annonc/mdf165. PMID: 12123342

Therapy

Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis.
Mullassery D, Farrelly P, Losty PD
Pediatr Hematol Oncol 2014 Nov;31(8):703-16. Epub 2014 Sep 23 doi: 10.3109/08880018.2014.947009. PMID: 25247398
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B
Pediatr Blood Cancer 2011 Apr;56(4):578-83. Epub 2010 Dec 9 doi: 10.1002/pbc.22693. PMID: 21298742
Management and outcome of stage 3 neuroblastoma.
Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK
Eur J Cancer 2009 Jan;45(1):90-8. Epub 2008 Nov 6 doi: 10.1016/j.ejca.2008.09.016. PMID: 18996003Free PMC Article
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK; Children's Oncology Group
Pediatr Blood Cancer 2009 Jan;52(1):44-50. doi: 10.1002/pbc.21784. PMID: 18937318Free PMC Article
Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.
Marcus KJ, Shamberger R, Litman H, von Allmen D, Grupp SA, Nancarrow CM, Goldwein J, Grier HE, Diller L
J Pediatr Hematol Oncol 2003 Dec;25(12):934-40. doi: 10.1097/00043426-200312000-00005. PMID: 14663275

Prognosis

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S
Clin Cancer Res 2023 Apr 14;29(8):1546-1556. doi: 10.1158/1078-0432.CCR-22-3032. PMID: 36749880Free PMC Article
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR
Pediatr Blood Cancer 2014 Nov;61(11):1932-9. Epub 2014 Jul 7 doi: 10.1002/pbc.25134. PMID: 25044743
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B
Pediatr Blood Cancer 2011 Apr;56(4):578-83. Epub 2010 Dec 9 doi: 10.1002/pbc.22693. PMID: 21298742
Management and outcome of stage 3 neuroblastoma.
Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK
Eur J Cancer 2009 Jan;45(1):90-8. Epub 2008 Nov 6 doi: 10.1016/j.ejca.2008.09.016. PMID: 18996003Free PMC Article
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK; Children's Oncology Group
Pediatr Blood Cancer 2009 Jan;52(1):44-50. doi: 10.1002/pbc.21784. PMID: 18937318Free PMC Article

Clinical prediction guides

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S
Clin Cancer Res 2023 Apr 14;29(8):1546-1556. doi: 10.1158/1078-0432.CCR-22-3032. PMID: 36749880Free PMC Article
Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma.
Okamoto Y, Kodama Y, Nishikawa T, Rindiarti A, Tanabe T, Nakagawa S, Yoshioka T, Takumi K, Kaji T, Kawano Y
Pediatr Hematol Oncol 2017 Apr;34(3):157-164. Epub 2017 Oct 4 doi: 10.1080/08880018.2017.1348414. PMID: 28976242
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR
Pediatr Blood Cancer 2014 Nov;61(11):1932-9. Epub 2014 Jul 7 doi: 10.1002/pbc.25134. PMID: 25044743
The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.
Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG
Pediatr Blood Cancer 2012 May;58(5):675-81. doi: 10.1002/pbc.23250. PMID: 22493777

Recent systematic reviews

Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis.
Mullassery D, Farrelly P, Losty PD
Pediatr Hematol Oncol 2014 Nov;31(8):703-16. Epub 2014 Sep 23 doi: 10.3109/08880018.2014.947009. PMID: 25247398

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...